These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran. Mahdavi-Mazdeh M, Zamyadi M, Norouzi S, Heidary Rouchi A. Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440 [Abstract] [Full Text] [Related]
5. Adherence to K/DOQI practice guidelines for bone metabolism and disease. Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W. Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187 [Abstract] [Full Text] [Related]
6. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E. Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962 [Abstract] [Full Text] [Related]
7. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice. Shastri J, Tran A, Covit A, Pepe J, Sherman RA. J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302 [Abstract] [Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L. Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [Abstract] [Full Text] [Related]
13. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Górriz JL, Molina P, Bover J, Barril G, Martín-de Francisco AL, Caravaca F, Hervás J, Piñera C, Escudero V, Molinero LM, en nombre de los investigadores del estudio OSERCE. Nefrologia; 2013 Jan 18; 33(1):46-60. PubMed ID: 23364626 [Abstract] [Full Text] [Related]
16. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL, Cases A. Nephrol Dial Transplant; 2006 Feb 18; 21(2):459-65. PubMed ID: 16263739 [Abstract] [Full Text] [Related]
17. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. Monge M, Shahapuni I, Oprisiu R, El Esper N, Morinière P, Massy Z, Choukroun G, Fournier A. Nat Clin Pract Nephrol; 2006 Jun 18; 2(6):326-36. PubMed ID: 16932454 [Abstract] [Full Text] [Related]
19. [Relationship between sevelamer HCl and vascular calcification]. Uemura K, Kakuta T, Saito A. Clin Calcium; 2007 Mar 18; 17(3):392-8. PubMed ID: 17339744 [Abstract] [Full Text] [Related]
20. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F. Nephrol Dial Transplant; 2008 Jul 18; 23(7):2319-23. PubMed ID: 18281320 [Abstract] [Full Text] [Related] Page: [Next] [New Search]